# Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

> **NCT07220135** · PHASE2 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab (or biosimilar)
- **DRUG:** Pertuzumab (or biosimilar)

## Key facts

- **NCT ID:** NCT07220135
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2027-11-14
- **Final completion:** 2031-05-14
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220135, "Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07220135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*